Canopy Biosciences Acquires Zellkraftwerk GmbH

Bruker Corporation Acquires Canopy Biosciences, LLC

September 11, 2020

Biotechnology

Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.

Ampersand Capital Partners Makes Growth Investment in GeneWerk GmbH

September 21, 2020

Biotechnology

Ampersand Capital Partners has made a majority growth equity investment in GeneWerk GmbH to expand the company's cell and gene therapy testing capabilities and support U.S. and European market expansion. GeneWerk, a Heidelberg-based clinical and preclinical testing laboratory known for vector integration site analysis and bioinformatics services, will use the capital to scale capabilities and meet rising demand for cell and gene therapy testing.

Canopy Biosciences Acquires Core Diagnostics

December 4, 2019

Biotechnology

Canopy Biosciences, a St. Louis-based multi-omic services company backed by Ampersand Capital Partners, has acquired Core Diagnostics, a California CLIA-certified biomarker analysis laboratory. The acquisition gives Canopy CLIA-certified laboratory capabilities to offer its multi-omic immune profiling services to clinical as well as preclinical and translational customers.

Biosynth Carbosynth Acquires Pepscan

July 4, 2022

Biotechnology

Biosynth Carbosynth, a KKR- and Ampersand-backed supplier of materials to the life-sciences industry, has acquired Pepscan, a Netherlands-based peptide discovery, optimization and GMP peptide manufacturing specialist. The deal adds Pepscan’s proprietary CLIPS technology and epitope-mapping capabilities to Biosynth’s peptide capabilities (including vivitide) to form a new global Peptide division serving pharma, biotech, diagnostics and cosmetics customers.

Ampersand Capital Partners Invests in Genezen Laboratories

January 5, 2021

Biotechnology

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.

Ampersand Capital Partners Acquires Biologos LLC

March 19, 2024

Biotechnology

Ampersand Capital Partners, a healthcare-focused private equity firm, has acquired Biologos LLC, a Glendale Heights, Illinois-based manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera. Ampersand will invest to expand Biologos' capabilities, product offerings, and geographic reach, and has appointed Frank Witney as Chairman with two Ampersand principals joining the board.